SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-21-142743
Filing Date
2021-04-30
Accepted
2021-04-30 08:32:52
Documents
4

Document Format Files

Seq Description Document Type Size
1 DEFA14A d176669ddefa14a.htm DEFA14A 35260
2 GRAPHIC g176669g31p51.jpg GRAPHIC 936
3 GRAPHIC g176669g41t13.jpg GRAPHIC 40926
4 GRAPHIC g176669g66n09.jpg GRAPHIC 9524
  Complete submission text file 0001193125-21-142743.txt   102067
Mailing Address 300 TECHNOLOGY SQUARE 2ND FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 2ND FLOOR CAMBRIDGE MA 02139 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39460 | Film No.: 21873919
SIC: 2836 Biological Products, (No Diagnostic Substances)